Comparative Pharmacology
Head-to-head clinical analysis: FUNGIZONE versus HALOTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FUNGIZONE versus HALOTEX.
FUNGIZONE vs HALOTEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to ergosterol in fungal cell membranes, forming pores that increase permeability, leading to leakage of intracellular contents and cell death.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
IV: 0.25-1 mg/kg/day as a single infusion; for aspergillosis, up to 1.5 mg/kg/day; maximum daily dose 1.5 mg/kg.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 15 days (range 10-20 days) after a single dose; with prolonged therapy, a prolonged terminal half-life of up to 15 days reflects slow redistribution from tissue depots.
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Primarily fecal (40-50%) via biliary elimination without metabolism; renal excretion of unchanged drug is minimal (<5% in 24 hours).
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Category C
Category C
Antifungal
Antifungal